Viracta Therapeutics Posts Data From Lymphoma Trial At ASH Presentation

Viracta Therapeutics Inc VIRX announced final data from its Phase 1b/2 trial of Nana-val in relapsed/refractory (R/R) EBV+ lymphoma.

  • The data were presented at the 2021 American Society of Hematology (ASH) Annual Meeting.
  • Nana-val was well tolerated and demonstrated activity with complete responses observed across multiple EBV+ lymphoma subtypes and a median duration of response of 10.4 months.
  • As of the October 28 data cutoff, 55 patients were enrolled. 
  • Nana-val was generally well tolerated with reversible low-grade toxicities. 
  • The most commonly observed treatment-emergent adverse events were reversible cytopenias, low-grade creatinine elevations, and gastrointestinal symptoms.
  • Among evaluable patients (n=43), an overall response rate of 40% was observed across all lymphoma subtypes.
  • Clinical Benefit Rate (CBR) was 56%.
  • The median duration of response was 10.4 months, with three patients achieving responses with durations over two years.
  • Last month, Viracta secured a $50 million credit facility from Silicon Valley Bank and Oxford Finance.
  • Price Action: VIRX shares are are down 5.71% at $3.96 during the market session on the last check Monday.
  • Check out our coverage of the American Society of Hematology (ASH) Annual Meeting 2021 here.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralASH21BriefslymphomaPhase 1 TrialPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!